Cancer Cell Therapy

Acute Myeloid Leukemia

Replased / Refractory

CCT5083
Phase I Study of WU-NK-101 in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML)
PI: Muffy Sponsor: Wugen, Inc.
Priority 1: IF Pre-Transplant
Priority 2: IF Post-Transplant Relapse

CCT5092
Phase I/II Study of Donor-Derived Anti-CD33 Chimeric Antigen Receptor Expressing T Cells (VAAR33) in Relapsed or Refractory Acute Myeloid Leukemia After Allogeneic Hematopoietic Cell Transplantation
PI: Muffy Sponsor: Vor Biopharma
Priority 1: IF Post-Transplant Relapse
Priority 2: IF Pre-Transplant

KEY

<table>
<thead>
<tr>
<th>Status</th>
<th>Icon</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pending</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Open for Enrollment</td>
<td>Link</td>
<td>Trial Posting</td>
</tr>
<tr>
<td>Observational Study</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Enrollment on Hold</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Please mark up a copy using black ink and email changes to SRC-office@stanford.edu